Drug intelligence / Profile preview

PB718

Development stage: Preclinical
Lead developer: PegBio
Administration: Subcutaneous

Overview

PB718 is a biologic therapeutic developed by PEG Biosciences for the treatment of drug addiction, specifically opioid addiction, and the management of pain. It is designed to target opioid receptors in the brain to reduce and prevent the effects of opiates, mitigate withdrawal symptoms, and minimize patient discomfort during the detoxification process. As a next-generation therapeutic, PB718 aims to provide a dual-purpose solution for both chronic pain and substance use disorders by modulating opioid receptor activity to prevent relapse.

Targets

GLP1R (GLP-1R)GCGR (Glucagon receptor)

Beyond the preview

Go deeper on PB718.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB718.

Explore the full profile